Supernus Pharmaceuticals | SUPN - Cash And Equivalent


Supernus Pharmaceuticals reported $151.37M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Abbott USD 8.52B 1.01B Dec/2025
ANI Pharmaceuticals USD 285.58M 22.98M Dec/2025
Aurora Cannabis CAD 95.69M 44.47M Sep/2025
Bristol-Myers Squibb USD 10.21B 5.52B Dec/2025
Canopy Growth CAD 298.06M 171.86M Sep/2025
Cara Therapeutics USD 20.65M 13.57M Jun/2025
Corcept Therapeutics USD 120.49M 4.64M Dec/2025
Eisai JPY 301.65B 16.27B Sep/2025
Eli Lilly USD 7.27B 2.52B Dec/2025
Novo Nordisk A/S DKK 18.44B 5.78B Jun/2025
Pacira USD 158.54M 10.96M Dec/2025
Perrigo USD 432.1M 22.1M Sep/2025
Pfizer USD 1.34B 295M Sep/2025
Supernus Pharmaceuticals USD 151.37M 6.66M Sep/2025
United Therapeutics USD 1.56B 217M Dec/2025
Xeris Pharmaceuticals USD 91.6M 32.32M Sep/2025